Evidence map›Paper›PMID 19755182›Full record

ReviewAdvances in immunology2009

Chapter 2: Kill the bacteria...and also their messengers?

Robert Munford, Mingfang Lu, Alan Varley

Open access · greenAbstract readReview
In one paragraph

Review in Advances in immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Time-Course Transcriptome Analysis of Lungs From Mice Infected With HypervirulentFrontiers in cellular and infection microbiology · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Sepsis: mechanisms of bacterial injury to the patient.Scandinavian journal of trauma, resuscitation and emergency medicine · 2019
    Review
  12. Article
  13. Crystal structure of the mammalian lipopolysaccharide detoxifier.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Robert MunfordDepartment of Internal Medicine, UT-Southwestern Medical Center, Dallas, Texas, USA.
Mingfang Lu
Alan Varley
The University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

INTERACTIONS OF ENDOTOXIN WITH PLASMA AND CELLSR01AI018188 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI VARLEY, ALAN WAYNE · 1985 to 2011
$3.9M
INTERACTIONS OF ENDOTOXIN WITH PLASMA AND CELLSR37AI018188 · NIAID · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MUNFORD, ROBERT S · 1992 to 2001
$729k
Interactions of Endotoxin with Plasma and CellsR56AI018188 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI MUNFORD, ROBERT S · 2007 to 2007
$523k
NIAID NIH HHS AI18188NIAID NIH HHS R01 AI018188NIAID NIH HHS R37 AI018188NIAID NIH HHS R56 AI018188
6 · The paper itself

Abstract

We consider here a previously neglected aspect of recovery from infectious diseases: how animals dispose of the dead microbes in their tissues. For one of the most important disease-causing microorganisms, Gram-negative bacteria, there is now evidence that the host catabolism of a key microbial molecule is essential for full recovery. As might be expected, it is the same bacterial molecule that animals sense to detect the presence of Gram-negative bacteria in their tissues, the cell wall lipopolysaccharide (LPS). Here, we discuss current knowledge about LPS sensing with emphasis on the host enzyme that inactivates this microbial "messenger" molecule. We also consider the possibility that the rate at which stimulatory microbial molecules undergo inactivation may influence the duration and severity of diseases caused by other infectious agents.

Indexed as

AnimalsAnti-Bacterial AgentsCarboxylic Ester HydrolasesGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansLipopolysaccharidesMicrobial Viabilityacyloxyacyl hydrolaseAnti-Bacterial AgentsCarboxylic Ester HydrolasesLipopolysaccharides

Identifiers

PMID19755182
PMCPMC2812913
OpenAlexW1538229013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.